In an industry first, LYPHE is bringing patients to the table to explore how to improve the patient experience across the organisation – and the wider industry.
Registration is now open for the company’s newly created Patient Representative Board, which will focus on patient concerns and issues in the medical cannabis industry.
It will be formed of independent patients from across the UK, Channel Islands and Isle of Man, as well as representatives from patient groups and charities.
Since the rescheduling of medical cannabis in November 2018, LYPHE has been a key player in patient access, with the large majority of patients using its clinical services and dispensary to obtain medication.
The teething pain and successes of the global medical cannabis industry have been well documented by commentators and patients alike.
Announcing the news, LYPHE said the industry’s first Patient Representative Board would ensure patient voices are heard.
Meetings will be held monthly, and feedback from the sessions will be used to further explore how to improve the patient experience.
By working together, LYPHE hopes to bring about changes that will benefit the wider patient community, as well as shape the organisation’s future direction.
Discussing the initiative, LYPHE Group Managing Director Jonathan Nadler, said: “I’m delighted LYPHE is taking the initiative in working closely with patients. We want to build a stronger, more sustainable industry whilst continuing our journey for full patient access.
“The issues that impact our business, and the medical cannabis industry, ultimately impact our patients, which is why improving transparency with patient groups is vital.”
For more information on how to apply visit www.lyphegroup.com.featured
Applicants or patient groups can register their interest by emailing their details along with reasons why they would like to join the Board via the contact form.
Membership will be limited to a total of 12 representatives in addition to the two chairs.
Grow Pharma launches new platform to help UK doctors learn about medical cannabis
The Journal Club will help inform UK doctors about the latest medical cannabis research.
Grow Pharma has launched a Journal Club to help inform UK doctors about the latest medical cannabis research.
The UK’s leading distributor of prescribed cannabis medicines, Grow Pharma, is now launching the latest in a string of initiatives aimed at educating doctors on cannabis medicines.
Each edition of the Journal Club will feature two recently published clinical papers relevant to the field of medical cannabis/cannabinoids from a variety of different disease areas including chronic pain, psychiatric disorders, neurology, and IBD, and will be released approximately every two weeks.
The clinical papers will be emailed out as well as hosted on Grow’s Doctor Portal where healthcare professionals will be able to comment on the articles and share thoughts and ideas with each other. The Doctor Portal also features recordings of past webinar educational sessions from medical cannabis experts, as well as news articles, information on medicines and discussion forums for doctors.
“Educating doctors really is the key to increasing the use and acceptance of medical cannabis in the UK,” commented Grow Pharma CEO, Pierre Van Weperen.
“We have had significant success in supporting new doctors on their journey towards prescribing medical cannabis. Many doctors want to be involved in multiple educational sessions and hear from others who are already prescribing. We facilitate those interactions. We also help to connect them to existing specialist cannabis clinics or help them set up their own clinics.”
There are now upwards of 15 clinics specialising in the prescription of cannabis medicines in the UK and on the Channel Islands.
Grow Pharma are proud to be the preferred distributor for more of these clinics than any other and is dedicated to supporting the clinics and doctors as they learn about medical cannabis, onboard new doctors and set themselves up as centres of expertise in the field. Grow puts its success down to having the broadest range of cannabis medicines available in the UK and their hard work and dedication to supporting doctors throughout the process.
The clinical papers featured in the Journal Club will be selected by Grow’s Medical Team for their high level of evidence and relevance to clinical areas where there is the most perceived potential to help patients.
In the UK, any specialist doctor can prescribe cannabis medicines within their field but not all doctors are aware of the potential benefits of cannabis medicines, even three years after they were rescheduled, due to a lack of formal education from clinical bodies. Grow Pharma believes that the Journal Club will help to bridge this gap in doctors’ knowledge.
“We all know how busy UK doctors are. It’s understandable they don’t always have the time to read about new treatments, especially one like medical cannabis, where there is so much to learn about the many ways it can help patients,” said Grow’s patient access lead Alex Fraser.
“The Journal Club is about making it easy and straightforward for Doctors to keep up-to-date with research and to continue learning about cannabis medicines, even if they are already prescribing them. We carefully select the studies and deliver them straight to their inbox in digestible chunks.
“If they have any more questions, they know that we’re on hand to answer them.”
Whilst the Doctor Portal is only accessible to healthcare professionals and the Journal Club is aimed at doctors, anyone can sign-up if they want to learn more about medical cannabis. The Journal Club is educational and non-promotional and solely designed to increase awareness of the latest research around this exciting field of medicine.
To sign up to Journal Club just click the link and fill in the short form here
Study: States with full legal access show fewer registered medical cannabis patients
“If true, this could have implications for public health and policy,” say researchers.
Study shows U.S states where cannabis is legal for recreational purposes have experienced a decrease in patients registering for medical cannabis programmes.
The study on different US states, published in the International Drug Journal, revealed that numbers of registered and active medical cannabis consumers increased while it was not legal for recreational use.
Researchers in Arizona took data from the medical cannabis registry from two dozen states between 2013 and 2020. These are mandatory registries that record the number of medical cannabis patients. They analysed the data to see if there were any changes around the times that recreational legalisation was introduced.
There are currently 19 states in the US that have legalised recreational cannabis including New Jersey, Vermont, Arizona and New York. However, more states have medical cannabis programs although some are still not operational. Some states such as Colorado have had recreational access since 2012, the year before the study was started.
Medical cannabis patients
The results confirmed that medical cannabis cardholders increased during times when recreational use was not legal. It then subsequently decreased when it became legal.
It also revealed an increase of 380 patients per 100,000 people per year when just medical cannabis was legal. This corresponded to a decrease of 100 patients per 100,000 after recreational cannabis was allowed. The researchers noted that active registered active male patients decreased faster than women. In states where only medical cannabis was legal, the older age groups (35 or older), increased faster.
They also found that in three states with medical-only use, the results showed significant increases in enrollment from 2016 to 2020 across white, African-American and Hispanic patients.
The researchers wrote: “There is speculation that enrollment in U.S. state medical cannabis programs differs depending on whether adult recreational cannabis use is legal. If true, this could have implications for public health and policy.”
“Findings suggest that recreational cannabis legalisation is associated with decreasing enrollment in medical cannabis programs, particularly for males.”
Latin American cannabis clinic Zerenia arrives in UK – promising patients more ‘affordable’ access
The clinic has recently joined Project Twenty21 with the promise of making medical cannabis more accessible.
Latin American medical cannabis clinic, Zerenia, has launched in the UK, with a bid to improve patient access as it joins Project Twenty21.
The clinic also offers competitive costs, with consultation fees at £80.
The clinic’s three doctors will initially prescribe for chronic pain and mental health, with the majority of patients so far seeking treatment for indications such as anxiety, ADHD, PTSD and insomnia.
Zerenia, which already has 14 clinics across Latin America, has treated around 14,000 patients with medical cannabis, and according to Zerenia’s UK clinical operations director, Freeda Solliman, mental health is the predominant indication prescribed for.
Many of these patients now get their prescriptions funded via private insurers, a model which the clinic now hopes to replicate in the UK.
“In Latin America we’ve built a body of evidence there to support private insurers to fund medical cannabis treatment,” Solliman told Cannabis Health.
“We’ve seen about 14,000 patients who have been treated with medical cannabis and a large number of those actually get their prescriptions funded by private insurers. That’s the kind of model that you want to bring here.”
Zerenia has partnered with T21, which subsidises the cost of prescriptions, to help build the growing body of evidence for the safety and efficacy of medical cannabis.
“Our goals are quite well aligned, we want to build the evidence and we want to make medical cannabis more affordable for patients,” continued Solliman.
“We want to work to encourage the NHS first and foremost, but also private insurers to fund at least part of the costs involved in being treated with medical cannabis.”
She added: “We did our research to understand some of the bottlenecks in the industry and how hard it is for some patients to go through the process, so we wanted to support patients through that and try to offer them more of a seamless experience.”
Zerenia is now taking on new patients who wish to join T21, or those who may want to try a different clinic.
Initial consultations for new patients are priced at £80, for those transfering from a different clinic, £40. Find more information here
Introducing our new B2B title
- My endometriosis was misdiagnosed as an eating disorder
- New research could have major implications for global drug-driving laws
- Find your balance with premium, vegan and cruelty-free CBD patches
- Long Covid: Experts explore the role of cannabinoids in treatment
- David Beckham-backed CBG skincare line launches new products
- Chronic pain and medical cannabis – “Without it my life stops”
News1 year ago
Community extends support to cannabis icon Rick Simpson
Case Studies2 years ago
CBD oil and fibromyalgia – a case study
News1 year ago
NHS lines up cannabis medicine manufacturing
News1 year ago
Cancer survivor claims cannabis oil helped her beat brain tumour
News11 months ago
UK grants second licence to grow high-THC medical cannabis
Insight1 year ago
I’ve gone from a wheelchair to walking thanks to cannabis
News1 year ago
Living with chronic fatigue – my CBD story
Feature1 year ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt